TREA

97599709 - NANT CANCER VACCINE

Follow

Information

  • Trademark
  • 97599709
  • Serial Number
    97599709
  • Filing Date
    September 20, 2022
    a year ago
  • Transaction Date
    May 29, 2024
    6 days ago
  • Status Date
    May 16, 2024
    19 days ago
  • Published for Opposition Date
    June 18, 2024
    13 days from now
  • Location Date
    May 16, 2024
    19 days ago
  • First Use Anywhere Date
    July 19, 2022
    a year ago
  • First Use In Commerce Date
    July 19, 2022
    a year ago
  • Status Code
    681
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    ALTREE, NICHOLAS
  • Attorney Docket Number
    155500-00418
    Attorney Name
    Michael J. McCue
  • Owners
Information
Mark Drawing Code
4
Mark Identification
NANT CANCER VACCINE
Case File Statements
  • GS0051: pharmaceutical preparations and substances for the treatment of human diseases in the nature of non-cancerous neoplasia, immunologic-related diseases, and immunologic dysfunction, animal diseases, autoimmune diseases, infectious diseases and cancer for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations and substances for the prevention, diagnosis, and treatment of human diseases in the nature of non-cancerous neoplasia, immunologic-related diseases, and immunologic dysfunction, animal diseases, autoimmune diseases, infectious diseases and cancer; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment of human diseases in the nature of non-cancerous neoplasia, immunologic-related diseases, and immunologic dysfunction, animal diseases, autoimmune diseases, infectious diseases and cancer; biological preparations for medical purposes, namely, vaccine preparations; low-dose chemotherapeutics, low dose radiopharmaceutical preparations, and personalized neoepitope-targeted pharmaceutical preparations for medical use for the treatment of human diseases in the nature of non-cancerous neoplasia, immunologic-related diseases, and immunologic dysfunction, animal diseases, autoimmune diseases, infectious diseases, and cancer; anti-cancer preparations; vaccines; biological preparations, namely, cell-derived preparations, cell therapeutics, monoclonal antibodies, cytokines, immune modulators, low-dose chemotherapeutics, low-dose radiation therapeutics, antibodies, fusion proteins, peptide and cytokine biological preparations, vaccines, personalized neoepitope-based therapeutics, and natural killer cell derived preparations, for the treatment of non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, autoimmune diseases, infectious diseases, animal diseases, and cancer for clinical, medicinal, therapeutic, and veterinary purposes; kits comprising cell cultures, reagents and related instructions, for use in the treatment and prevention of non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, autoimmune diseases, infectious diseases, animal diseases and cancer, for clinical, medicinal, therapeutic and veterinary purposes
  • DS0000: "CANCER VACCINE"
Case File Event Statements
  • 9/23/2022 - a year ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 9/26/2022 - a year ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 6/29/2023 - 11 months ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 8/21/2023 - 9 months ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 8/21/2023 - 9 months ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 8/21/2023 - 9 months ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 11/21/2023 - 6 months ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 11/21/2023 - 6 months ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 11/21/2023 - 6 months ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 2/15/2024 - 3 months ago
    12 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 2/15/2024 - 3 months ago
    10 - FINAL REFUSAL WRITTEN Type: CNFR
  • 2/15/2024 - 3 months ago
    11 - FINAL REFUSAL E-MAILED Type: GNFR
  • 5/14/2024 - 21 days ago
    13 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 5/14/2024 - 21 days ago
    16 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 5/14/2024 - 21 days ago
    14 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 5/14/2024 - 21 days ago
    15 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 5/14/2024 - 21 days ago
    17 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 5/29/2024 - 6 days ago
    18 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP